MarginsXMarginsX
Home › Markets › Health Care › MREO

Mereo BioPharma Group plc (MREO)

MREO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3050
-0.81% on the day
Market cap
$48.7M
Nano cap
Revenue · 2025
$500K
Prior year not contiguous
Net income · 2025
-$41.9M
-8375.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1719714/000119312526115226/0001193125-26-115226-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMREO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited Kingdom
IPO yearNot reported by the screener
SEC CIK0001719714
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$500K
Net income-$41.9M
Operating income-$40.1M
Net margin-8375.6%
Operating margin-8021.4%
Revenue growthNo prior-year revenue to compare
Cash$41.0M
Total assets$45.9M
P/E (computed)Net income was not positive
P/S (computed)97.4×

Warning signs

Cash runway
14.2 months
$26.1M cash at September 30, 2026
Share count, 1 year
+0.4%
2025-11-10 to 2026-11-09 · +13.9% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$26.1M cash; operating cash flow -$5.5M a quarter.Report 2026-09-30
Shares outstanding159,700,637 (2026-11-09); 159,131,701 a year earlier; 140,257,406 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-19
AuditorPricewaterhouseCoopers LLP, Reading, United KingdomPCAOB Form AP 2026-04-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$800K-$5.9M-$4.1M$26.1MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
$0-$7.0M-$6.0M$30.1MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q1 2026
2026-03-31
Not filed-$6.7M-$4.3M$30.1MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
$0-$7.4M-$7.7M$41.0M$0$500K10-K 2026-03-19
Q3 2025
2025-09-30
$0-$7.0M-$7.3M$48.7M$0Needs four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
$500K-$14.6M-$7.7M$56.1M$0Needs four quarters10-Q 2026-08-11
Q1 2025
2025-03-31
Not filed-$12.9M-$8.3M$62.5M$0Needs four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
$0-$7.0M-$9.4M$69.8M$5.5M$010-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32024-12-04
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEF 14A2026-04-09

Source: SEC EDGAR submissions feed, 441 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+8.8%
1 month-3.7%
3 months0.0%
Year to date-26.1%
1 year-82.7%
From 52-week high-86.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
HOWLWerewolf Therapeutics Inc.$0.9908+1.07%$48.2M
CTORCitius Oncology Inc.$0.5350-6.76%$49.7M
IBIOiBio Inc.$0.7067-3.42%$49.8M
RFLRafael Holdings Inc.$0.9701-9.34%$50.6M
ATNMActinium Pharmaceuticals Inc. (Delaware)$1.49-9.15%$46.8M
ANVSAnnovis Bio Inc.$0.7500-19.02%$46.5M
QUCYQuantum Cyber N.V.$0.5850-7.58%$51.0M
RNXTRenovoRx Inc.$0.9549-8.18%$46.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier